vtvtherapeutics.com
Press Releases | vTv Therapeutics
http://vtvtherapeutics.com/press-releases/archives
Treatments for the Advancement of Life. Filter Press Releases by Year. TransTech Pharma and Calithera Biosciences Enter Into Worldwide Licensing Agreement for Hexokinase II Inhibitor Program. March 5, 2015. Read more about TransTech Pharma and Calithera Biosciences Enter Into Worldwide Licensing Agreement for Hexokinase II Inhibitor Program. TransTech Pharma, LLC Announces Agreement with FDA on Special Protocol Assessment for TTP488 Phase 3 Trial in Patients with Mild Alzheimer's Disease. July 10, 2014.
vtvtherapeutics.com
Management | vTv Therapeutics
http://vtvtherapeutics.com/management
Treatments for the Advancement of Life. Stephen L. Holcombe, B.Sc. President, Chief Executive Officer. Rudy Howard, B.A., CPA. EVP, Chief Financial Officer. Larry Altstiel, M.D., Ph.D. EVP, Chief Medical Officer. Robin E. Abrams, J.D. Executive Vice President, General Counsel. Aaron Burstein, PharmD. SVP, Clinical Development. Carmen Valcarce, Ph.D. SVP, Chief Scientific Officer. Robert C. Andrews, Ph.D. Imogene Dunn, Ph.D. SVP, BioMetrics and Regulatory. Samuel B. Rollins, Ph.D.,J.D.
vtvtherapeutics.com
TTP399 | vTv Therapeutics
http://vtvtherapeutics.com/pipeline/ttp399
Treatments for the Advancement of Life. Studies in humans, along with numerous animal studies, showing that mutations in the gene encoding GK can cause both hyperglycemia ([diabetes mellitus]) and hypoglycemia (glucose levels below normal) depending on the mutation, confirm the critical role of GK in the regulation of glucose control and provide genetic validation for this target. TTP399 is currently being studied in a six-month phase 2b trial, the AGATA study. The A. Valcarce C. The Importance of Ti...
vtvtherapeutics.com
Publications, Presentations and Posters | vTv Therapeutics
http://vtvtherapeutics.com/publications
Treatments for the Advancement of Life. Publications, Presentations and Posters. Links to the following publications and presentations, which are located on outside websites, are provided for informational purposes only and do not constitute the opinions or views of vTv Therapeutics. Sabbagh MN, Agro A, Bell J, Aisen PS, Schweizer E, Galasko D. PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzeimer disease. Alzheimer Dis Assoc Disord 2011;25(3):206-212. Burstei...
vtvtherapeutics.com
vTv Therapeutics Inc. Announces Launch of Initial Public Offering | vTv Therapeutics
http://vtvtherapeutics.com/press-releases/2015/july/vtv-therapeutics-inc-announces-launch-initial-public-offering
Treatments for the Advancement of Life. VTv Therapeutics Inc. Announces Launch of Initial Public Offering. High Point, North Carolina (July 20, 2015). Or Stifel, Nicolaus and Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, CA 94104, Attention: Syndicate, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. You should keep in mind that any forward-looking statement made by the Company herein, or elsewhere, speaks only as of the date on which made. New risks...
vtvtherapeutics.com
HexoKinase II Inhibitors | vTv Therapeutics
http://vtvtherapeutics.com/pipeline/hexokinase-ii-inhibitors
Treatments for the Advancement of Life. Licensed to Calithera Biosciences, Inc.). Inhibition of glycolysis can be done without significant side effects, and such treatment will be additive to most known cancer therapies. HK2 enzyme inhibitors have been identified and human tumor xenograft studies in models of ovarian, pancreatic and lung cancers are ongoing. Designed by vTv Therapeutics.
vtvtherapeutics.com
Press Releases | vTv Therapeutics
http://vtvtherapeutics.com/press-releases
Treatments for the Advancement of Life. Filter Press Releases by Year. VTv Therapeutics Reports Third Quarter Financial and Operational Results and Recent Highlights. November 2, 2016. Read more about vTv Therapeutics Reports Third Quarter Financial and Operational Results and Recent Highlights. VTv Therapeutics to Present at Peptide Therapeutics Symposium. October 24, 2016. Read more about vTv Therapeutics to Present at Peptide Therapeutics Symposium. VTv Therapeutics to Present at Neuro Advance Boston.
vtvtherapeutics.com
HPP593 | vTv Therapeutics
http://vtvtherapeutics.com/pipeline/hpp593
Treatments for the Advancement of Life. HPP593 is a functionally selective peroxisome proliferator-activated receptor delta ( PPAR-delta ) agonist that is to begin a Phase 2 trial for the prevention of muscle weakness associated with PMV and critical injury. Designed by vTv Therapeutics.
vtvtherapeutics.com
vTv Therapeutics Appoints Rudy Howard as Chief Financial Officer | vTv Therapeutics
http://vtvtherapeutics.com/press-releases/2015/june/vtv-therapeutics-appoints-rudy-howard-chief-financial-officer
Treatments for the Advancement of Life. VTv Therapeutics Appoints Rudy Howard as Chief Financial Officer. High Point, North Carolina (June 29, 2015). VTv Therapeutics LLC (vTv), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced the appointment of Rudy C. Howard as Chief Financial Officer. About vTv Therapeutics LLC. Designed by vTv Therapeutics.
vtvtherapeutics.com
vTv Therapeutics Inc. Announces Pricing of Initial Public Offering | vTv Therapeutics
http://vtvtherapeutics.com/press-releases/2015/july/vtv-therapeutics-inc-announces-pricing-initial-public-offering
Treatments for the Advancement of Life. VTv Therapeutics Inc. Announces Pricing of Initial Public Offering. High Point, North Carolina (July 29, 2015). The Company intends to use the net proceeds of the offering to fund the STEADFAST Study (its ongoing Phase 3 trial of. Piper Jaffray and Co. and Stifel are acting as joint book-running managers for the offering. In addition, Canaccord Genuity Inc. and Janney Montgomery Scott LLC are acting as co-managers for the offering. VTv Therapeutics Inc. is a cl...
